You are here

  • Home
  • Online First
  • Response to: ‘Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’’ by Kaklamanos et al

Article Text

Article menu

Download PDFPDF

Correspondence response
Response to: ‘Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’’ by Kaklamanos et al
Free
  1. Sofia Ramiro1,2,
  2. Rémy L M Mostard3,
  3. Robert B M Landewé1,4
  1. 1Rheumatology, Zuyderland Medical Center, Heerlen, The Netherlands
  2. 2Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
  3. 3Department of Pulmonology, Zuyderland Medical Centre Heerlen, Heerlen, The Netherlands
  4. 4Amsterdam Rheumatology Center, AMC, Amsterdam, The Netherlands
  1. Correspondence to Dr Sofia Ramiro, Department of Rheumatology, Zuyderland Medical Center, 6419 PC Heerlen, Limburg, The Netherlands; sofiaramiro{at}gmail.com

http://dx.doi.org/10.1136/annrheumdis-2021-220474

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We have read with interest the letter by Kaklamanos et al1 pertaining to our COVID-19 High-intensity Immunosuppression in Cytokine storm syndrome (CHIC) study.2 Kaklamanos et al share their positive experience with tocilizumab administered to three patients with severe COVID-19 pneumonia, accompanied by signs of hyperinflammation, as described in our CHIC study.1 These descriptions perfectly match with our clinical experience regarding the use of tocilizumab in such critically ill patients and mirror the patients we have described in our CHIC study.2 Fortunately, the benefits of tocilizumab in such patients have meanwhile also been confirmed in randomised controlled trials, which hopefully paves the way, although with significant delay, for a more widespread use in COVID-19 patients who need it.3–5

    References

    1. ↵
      1. Kaklamanos A,
      2. Karamichalos P,
      3. Vlachoyiannopoulos P
      . Correspondence on “Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19- associated cytokine storm syndrome: results of the CHIC study”. Ann Rheum Dis 2021.doi:10.1136/annrheumdis-2021-220411
    2. ↵
      1. Ramiro S,
      2. Mostard RLM,
      3. Magro-Checa C, et al
      . Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the chiC study. Ann Rheum Dis 2020;79:1143–51.doi:10.1136/annrheumdis-2020-218479pmid:http://www.ncbi.nlm.nih.gov/pubmed/32719045
      OpenUrlAbstract/FREE Full Text
    3. ↵
      1. Salama C,
      2. Han J,
      3. Yau L, et al
      . Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med 2021;384:20–30.doi:10.1056/NEJMoa2030340pmid:http://www.ncbi.nlm.nih.gov/pubmed/33332779
      OpenUrlCrossRefPubMed
    4. ↵
      1. Remap-Cap-Investigators GAC,
      2. Mouncey PR, et al
      . Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med 2021.doi:10.1056/NEJMoa2100433
    5. ↵
      1. Landewé RBM,
      2. Ramiro S,
      3. Mostard RLM
      . COVID-19-induced hyperinflammation, immunosuppression, recovery and survival: how causal inference may help draw robust conclusions. RMD Open 2021;7:e001638.doi:10.1136/rmdopen-2021-001638pmid:http://www.ncbi.nlm.nih.gov/pubmed/33790049
      OpenUrlAbstract/FREE Full Text

    Footnotes

    • Handling editor Josef S Smolen

    • Contributors SR drafted the response. All authors reviewed and approved the final response.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles